YZJ-1139 + escitalopram

YZJ-1139 + escitalopram is an experimental oral combination therapy consisting of YZJ-1139, a dual orexin receptor antagonist developed for the treatment of insomnia disorder, and escitalopram, a selective serotonin reuptake inhibitor (SSRI) primarily indicated for major depressive disorder and generalized anxiety disorder. YZJ-1139 works by blocking orexin-1 and orexin-2 receptors, thereby suppressing wakefulness to promote sleep, while escitalopram increases extracellular serotonin by inhibiting its reuptake into presynaptic neurons, improving mood and anxiety symptoms. This combination is under clinical investigation to evaluate pharmacodynamic, pharmacokinetic, and safety profiles when co-administered[1][2].

Brand names

Cipralex

Other names

FazamorexantS(+)-Citalopram(S)-Citalopram